Business
Halozyme to Participate at Upcoming Investor Conferences
SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host investor meetings at the following investor conferences. \nDetails on the Company's participation are as follows:\nEvent:\n2025 Wells Fargo Healthcare Conference\nFormat:\nFireside Chat and 1x1 Meetings\nPresentation Date:\nThursday, September 4, 2025\nPresentation Time:\n10:30am PT / 1:30pm ET\nLocation:\nBoston, MA\nEvent:\nMorgan Stanley 23rd Annual Global Healthcare Conference\nFormat:\nFireside Chat and 1x1 Meetings\nDate:\nMonday, September 8, 2025\nPresentation Time:\n4:45am PT / 7:45am ET\nLocation:\nNew York, NY\n \nEvent:\n \nH.C. Wainwright 27th Annual Global Investment Conference\nFormat:\n1x1 Meetings\nDate:\nTuesday, September 9, 2025\nLocation:\nNew York, NY\nA live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.\nAbout Halozyme\nHalozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.\nHalozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and ...